AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$MANE

MONTANOVA CAPITAL, LLC (Cowen Aaron) sold $80.4M of MANE (indirect holdings)

MONTANOVA CAPITAL, LLC sold 750,000 indirectly-held shares of Veradermics, Inc (MANE) at $107.25 ($80.44M total) across 2 trades on 2026-08-19. Filed jointly with Cowen Aaron, Averill Master Fund, Ltd. (Director) and Averill Madison Master Fund, Ltd. (Director).

Original reporting
SEC EDGAR · MONTANOVA CAPITAL, LLC, Cowen Aaron, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.
Published Aug 21, 2026, 10:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MANE
Bearish
high confidence
Mentioned
$MANE
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANEBearishMed
01

Why it matters

The $80.4M sale reduces insider ownership, potentially influencing investor sentiment and short-term price action.

02

Market read

Newly disclosed insider sale of significant size; may prompt traders to reassess position in MANE.

03

What to watch

Sale was executed via open market, not a block trade, possibly minimizing market impact.

Relevance 8/10Novelty 8/10Timing: filed Aug 21, 2026

Background

Form 4 filings disclose insider transactions; director sales are closely watched for signals.

Company-level read

Ticker impact

$MANEBearishHigh confidence
Context

Director Montanova Capital sold 750,000 shares for $80.4M, reducing its stake to 461,033 shares.

Expected impact

Potential short-term downside pressure.

Evidence & confidence

Large $80M sale by a director is material and newly disclosed via Form 4.

Market effects

Sector

May affect perception of the biotech/healthcare sector if insider sells are viewed as a red flag.

Regional

Limited to US markets where MANE trades.

Global

Low, primarily relevant to investors in MANE.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    Veradermics, Inc.

    Issuer of the shares sold.

  • Insider
    Montanova Capital, LLC

    Director and reporting entity.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MANE insider trading history →

Related articles

AUG 11
$MANEMed

Veradermics, Inc (MANE): Results of Operations and Financial Condition

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q226earnings.htm EX-99.1 Document Exhibit 99.1 Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair los

SEC EDGAR 8-K6 min
JUL 15
$MANEMedAI 8/10

Veradermics' Oral Hair Loss Drug For Women Shows Results In Just 2 Months - Veradermics (NYSE:MANE)

Veradermics (NYSE:MANE) reported positive Phase 2 results for VDPHL01 in women with female pattern hair loss. In a 6-month study at 4.5 mg once daily or twice daily, hair count increased about 22.7 and 23.3 hairs/cm², respectively. By month six, 88.9% and 90% reported improved coverage, with no treatment-related serious adverse events. Shares were up 15.01% to $126.71.

benzinga.com4 min
JUL 15
$MANEMedAI 8/10

Extended-Release Oral Minoxidil Posts First Efficacy Win in Women With Hair Loss

Veradermics (NYSE: MANE) said its extended-release oral minoxidil tablet VDPHL01 showed clinically meaningful hair growth in women with female pattern hair loss in Phase 2 Study 207. In 22 women over 6 months, once-daily and twice-daily doses increased non-vellus hair counts by 22.7 and 23.3 hairs/cm², with no treatment-related serious adverse events. Enrollment for Study 306 continues; topline expected H1 2027.

techtimes.com6 min